Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 4

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Ovarian Neoplasms 4Fallopian Tube Neoplasms 3Carcinoma, Ovarian Epithelial 2Peritoneal Neoplasms 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × oregovomab × 1 year × Clear all
NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

CanariaBio Inc.

Phase 1/2 Active not recruiting
54 enrolled
Gynecologic

Ovarian Neoplasms

NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

CanariaBio Inc.

Phase 2 Active not recruiting
10 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04498117 2026-04-01

FLORA-5

CanariaBio Inc.

Phase 3 Active not recruiting
615 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05605535 2026-04-01

Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer

CanariaBio Inc.

Phase 2 Active not recruiting
88 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡